Latest News

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan 

>> DEP® patient case studies

>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received

>> New DEP® ADC programs

>> DEP® pipeline targets multiple high-value areas

>> Other DEP® programs

>> Outlook, recent news & events

 

Read More

DEP® irinotecan phase 2 commences after positive phase 1 results

May 7th, 2020

Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.

Read More

Starpharma presents at Macquarie Australia Conference

May 5th, 2020

Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.

Read More

SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)

Apr 15th, 2020

Starpharma today announced that its proprietary VivaGel® active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19. The finding was also significant given that SPL7013 was reported to be the best performing test compound against SARS-CoV-2 in the laboratory’s assay to date. With these positive results, Starpharma is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.

 

 

Read More

In the media

Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)

May 18th, 2020

The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.

Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.be

Read More

Starpharma CEO Dr Jackie Fairley on ausbiz

May 11th, 2020

Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.

To watch the full interview click here

Read More

Australia’s biotech sector tests multiple agents to fight COVID-19

Apr 22nd, 2020

US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.

To read the full article, click here

Read More

Condom gel compound proves effective against COVID-19

Apr 16th, 2020

The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel® portfolio.

To read the full article, click here (paywall).

 

Read More

Shareholder Updates

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan 

>> DEP® patient case studies

>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received

>> New DEP® ADC programs

>> DEP® pipeline targets multiple high-value areas

>> Other DEP® programs

>> Outlook, recent news & events

 

Read More

Shareholder Update January 2020

Jan 30th, 2020

In this issue: 

>> VivaGel® BV launched in the UK

>> AstraZeneca first DEP® product enters the clinic; triggers US$3M milestone

>> DEP® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel® condom receives regulatory approval in Europe

>> DEP® docetaxel & DEP® cabazitaxel clinical trial case studies

>> DEP® irinotecan phase 1/2 trial

>> New candidate - DEP® gemcitabine

>> GMP DEP® facility licence

>> DEP® combinations add further value

>> Outlook, recent news & events

Read More

Sign up to receive news here